OFFICE LEASE AGREEMENT between RJ EQUITIES LP (Landlord) and COGNITITION THERAPEUTICS, INC. (Tenant) Dated: July 1, 2017Office Lease Agreement • July 19th, 2021 • Cognition Therapeutics Inc • Biological products, (no disgnostic substances) • Pennsylvania
This Office Lease Agreement (the “Lease”) is made this day of July, 2017, by and between RJ EQUITIES LP, a Pennsylvania limited partnership (“Landlord”) and COGNITION THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
LEASE AGREEMENT BETWEEN 2500/2700 WESTCHESTER AVENUE OWNER SPE LLC, a Delaware Limited Liability Company, LANDLORD, -AND- COGNITION THERAPEUTICS, INC., a Delaware Corporation, TENANT Dated July 1, 2021Lease Agreement • July 19th, 2021 • Cognition Therapeutics Inc • Biological products, (no disgnostic substances) • New York
This LEASE AGREEMENT (this “Lease”) is dated July 1, 2021 and is between 2500/2700 WESTCHESTER AVENUE OWNER SPE LLC, a Delaware limited liability company (“Landlord”), and COGNITION THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
COGNITION THERAPEUTICS, INC. THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT March 20, 2014Investors’ Rights Agreement • July 19th, 2021 • Cognition Therapeutics Inc • Biological products, (no disgnostic substances) • Delaware
THIS THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT is made as of the 20th day of March, 2014, by and among Cognition Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors listed on Schedule A hereto, each of whom is referred to in this Agreement as an “Investor” and any Additional Purchaser (as defined in the Purchase Agreement) that becomes a party to this Agreement in accordance with Section 6.9.
Cognition Therapeutics Inc. 2403 Sidney Street Pittsburgh PA 15203 t: 412 481 2210 f: 412 481 2216Employment Agreement • July 19th, 2021 • Cognition Therapeutics Inc • Biological products, (no disgnostic substances) • Pennsylvania
COGNITION THERAPEUTICS, INC. 2021 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT GRANT NOTICE ANDRestricted Stock Unit Grant Agreement • July 19th, 2021 • Cognition Therapeutics Inc • Biological products, (no disgnostic substances) • Delaware
Cognition Therapeutics, Inc., a Delaware corporation (the “Company”), pursuant to its 2021 Equity Incentive Plan (the “Plan”), hereby grants to the individual listed below (“Participant”) the number of restricted stock units set forth below (the “Restricted Stock Units”). The Restricted Stock Units described in this Restricted Stock Unit Grant Notice (the “Grant Notice”) are subject to the terms and conditions set forth in the Award Agreement attached hereto as Exhibit A (the “Agreement”) and the Plan, each of which is incorporated herein by reference. Unless otherwise defined herein, capitalized terms used in this Grant Notice and the Agreement will have the meanings defined in the Plan.
SEPARATION AND RELEASE AGREEMENTSeparation and Release Agreement • July 19th, 2021 • Cognition Therapeutics Inc • Biological products, (no disgnostic substances) • Pennsylvania
THIS SEPARATION AND RELEASE AGREEMENT (this “Agreement”) is made by and between Kenneth I. Moch (the “Executive”) and Cognition Therapeutics, Inc. (the “Company”).
ADVISOR SERVICES AGREEMENTAdvisor Services Agreement • July 19th, 2021 • Cognition Therapeutics Inc • Biological products, (no disgnostic substances) • Pennsylvania
This Advisor Services Agreement (“Agreement”), effective as of March 17, 2020, is made between Cognition Therapeutics, Inc. (the “Company”) and Kenneth I. Moch (“Advisor”).
EMPLOYMENT AGREEMENTEmployment Agreement • July 19th, 2021 • Cognition Therapeutics Inc • Biological products, (no disgnostic substances) • Pennsylvania
EMPLOYMENT AGREEMENT effective as of June 1, 2020 (this “Agreement”) between Cognition Therapeutics, Inc. (the “Company”), a Delaware corporation, and Lisa Ricciardi (the “Executive”).
COGNITION THERAPEUTICS, INC. 2021 EQUITY INCENTIVE PLAN STOCK OPTION GRANT NOTICE ANDStock Option Grant Agreement • July 19th, 2021 • Cognition Therapeutics Inc • Biological products, (no disgnostic substances) • Delaware
Cognition Therapeutics, Inc., a Delaware corporation (the “Company”), pursuant to its 2021 Equity Incentive Plan (the “Plan”), hereby grants to the individual listed below (“Participant”) an option to purchase the number of Shares set forth below (the “Option”). The Option described in this Stock Option Grant Notice (the “Grant Notice”) is subject to the terms and conditions set forth in the Award Agreement attached hereto as Exhibit A (the “Agreement”) and the Plan, each of which is incorporated herein by reference. Unless otherwise defined herein, capitalized terms used in this Grant Notice and the Agreement will have the meanings defined in the Plan.
FIRST AMENDMENT TO OFFICE LEASE AGREEMENTOffice Lease Agreement • July 19th, 2021 • Cognition Therapeutics Inc • Biological products, (no disgnostic substances)
This First Amendment to Office Lease Agreement (“Amendment”) is made this 1st day of July, 2017, and is by and between RJ EQUITIES LP, a Pennsylvania limited partnership (“Landlord”), and COGNITION THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
FIRST AMENDMENT TO THIRD AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENTInvestors’ Rights Agreement • July 19th, 2021 • Cognition Therapeutics Inc • Biological products, (no disgnostic substances) • Delaware
THIS FIRST AMENDMENT (the “First Amendment”) to that certain Third Amended and Restated Investors’ Rights Agreement dated as of March 20, 2014, among Cognition Therapeutics, Inc., a Delaware corporation (the “Company”) and its stockholders party thereto (the “Investors’ Rights Agreement”), is entered into as of March 23, 2020, by and among the Company and the undersigned stockholders of the Company constituting the holders of at least 60% of the Registrable Securities (as defined in the Investors’ Rights Agreement) then outstanding (the “Required Investors”). All capitalized terms used but not defined in this First Amendment shall have the meanings assigned to them in the Investors’ Rights Agreement.
